- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lucid Diagnostics Inc (LUCD)
Track the Lucid Diagnostics share price today and view real-time LUCD share price data, including charts, technicals, and key financials. View the LUCD premarket stock price ahead of the market session or assess the after hours quote. Explore LUCD stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Lucid Diagnostics Stock Price Today?
The Lucid Diagnostics stock price today is 1.1200.
What Is the Stock Symbol for Lucid Diagnostics?
The stock symbol for Lucid Diagnostics is ""LUCD.""
What Stock Exchange Does Lucid Diagnostics Trade On?
Lucid Diagnostics is listed and trades on the NASDAQ stock exchange.
Is Lucid Diagnostics a Good Stock to Buy?
Determining whether Lucid Diagnostics or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUCD quote. (ISIN: US54948X1090)
What Is the Lucid Diagnostics Stock Price Today?
The Lucid Diagnostics stock price today is 1.1200.
What Is the Stock Symbol for Lucid Diagnostics?
The stock symbol for Lucid Diagnostics is ""LUCD.""
What Stock Exchange Does Lucid Diagnostics Trade On?
Lucid Diagnostics is listed and trades on the NASDAQ stock exchange.
Is Lucid Diagnostics a Good Stock to Buy?
Determining whether Lucid Diagnostics or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUCD quote. (ISIN: US54948X1090)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0901
1.1650
52 wk Range
0.9495
1.8000
LUCD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.09011.1650
52 wk Range
0.94951.8000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LUCD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
3.9500
Upside
+252.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Lucid Diagnostics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Lucid Diagnostics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc SWOT Analysis
Market Disruption | Lucid Diagnostics aims to revolutionize BE-EAC screening with EsoGuard/EsoCheck technology, targeting a $25 billion U.S. market opportunity |
Financial Crossroads | Despite 179% YoY revenue growth, LUCD faces challenges with cash burn and revised 2025 revenue projections, reflecting market uncertainties |
Reimbursement Hurdles | Progress in clinical validation studies bolsters reimbursement efforts, but pricing pressures could impact future revenue and market adoption |
Strategic Outlook | Analysts set price targets between $2.00 and $3.00, as LUCD navigates growth challenges and explores potential market expansion opportunities |
Lucid Diagnostics Inc Earnings Call Summary for Q4/2025
- Lucid Diagnostics posted Q4 2025 revenue of $1.5M, beating estimates by 7.91%, though EPS of -$0.10 missed forecasts; stock rose 2.52% premarket.
- Test volumes surged 29% sequentially in Q4, driven by strategic focus on Medicare and VA market expansion with $34.7M cash on hand.
- Company projects FY2026 revenue of $4.5M and FY2027 revenue of $10.1M, with expected EPS losses of -$0.31 and -$0.28 respectively.
- Operating expenses climbed 9.9% to $48.7M in 2025, while quarterly cash burn averaged $11.1M amid ongoing reimbursement challenges.
Last Updated: 27/03/2026, 12:50 am
Read Full TranscriptCompare LUCD to Peers and Sector
Metrics to compare | LUCD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLUCDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −0.1x | −0.4x | |
PEG Ratio | −0.08 | 0.05 | 0.00 | |
Price/Book | −4.4x | 1.1x | 2.6x | |
Price / LTM Sales | 40.5x | 1.7x | 3.1x | |
Upside (Analyst Target) | 167.9% | 65.5% | 58.6% | |
Fair Value Upside | Unlock | 31.1% | 8.2% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.9500
(+252.68% Upside)
Earnings
Latest Release
26/03/2026
EPS / Forecast
-0.10 / -0.09
Revenue / Forecast
1.5M / 1.39M
People Also Watch
FAQ
What Is the Lucid Diagnostics (LUCD) Stock Price Today?
The Lucid Diagnostics stock price today is 1.1200 USD.
What Stock Exchange Does Lucid Diagnostics Trade On?
Lucid Diagnostics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lucid Diagnostics?
The stock symbol for Lucid Diagnostics is "LUCD."
What Is the Lucid Diagnostics Market Cap?
As of today, Lucid Diagnostics market cap is 190.8100M USD.
What Is Lucid Diagnostics's Earnings Per Share (TTM)?
The Lucid Diagnostics EPS (TTM) is -0.6920.
When Is the Next Lucid Diagnostics Earnings Date?
Lucid Diagnostics will release its next earnings report on 18/05/2026.
From a Technical Analysis Perspective, Is LUCD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Lucid Diagnostics Stock Split?
Lucid Diagnostics has split 0 times.
How Many Employees Does Lucid Diagnostics Have?
Lucid Diagnostics has 82 employees.
What is the current trading status of Lucid Diagnostics (LUCD)?
As of 28/03/2026, Lucid Diagnostics (LUCD) is trading at a price of 1.1200 USD, with a previous close of 1.1500 USD. The stock has fluctuated within a day range of 1.0901 USD to 1.1650 USD, while its 52-week range spans from 0.9495 USD to 1.8000 USD.
What Is Lucid Diagnostics (LUCD) Price Target According to Analysts?
The average 12-month price target for Lucid Diagnostics is 3.9500 USD, with a high estimate of 8.25 USD and a low estimate of 2.5 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +252.68% Upside potential.
What Is the LUCD Premarket Price?
LUCD's last pre-market stock price is 1.1071 USD. The pre-market share volume is 200.0000, and the stock has decreased by -0.0429, or -3.7300%.
What Is the LUCD After Hours Price?
LUCD's last after hours stock price is 1.1292 USD, the stock has decreased by 0.0092, or 0.8200%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.